Results 141 to 150 of about 12,430 (191)

Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies. [PDF]

Front Cell Dev Biol
Yamamoto M, Hirakata H, Toda K.
europepmc   +1 more source

Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model. [PDF]

ACS Chem Neurosci
Kandilakis CL, Papatheodoropoulos C.
europepmc   +1 more source

Elevated serotonin receptor 2A signaling restores learning and memory in a Fragile X syndrome model. [PDF]

Sci Rep
Du Y, Miller VK, Mellies AJ, Broadie K.
europepmc   +1 more source

SERAAK2 as a Serotonin Receptor Ligand: Structural and Pharmacological In Vitro and In Vivo Evaluation. [PDF]

Molecules
Kaczor AA, Zięba A, Karcz T, Jastrzębski MK, Szczepańska K, Laitinen T, Castro M, Kędzierska E.   +7 more
europepmc   +1 more source

Stereoselective, sex-dependent 5-HT_2A receptor modulation of cortical plasticity by MDMA in mice. [PDF]

Neuropsychopharmacology
Gaines-Smith MC, Silverman JM, Fiorillo M, Younkin J, Moore KN, Maltman JL, de la Fuente Revenga M, Wolstenholme JT, Glennon RA, Dukat M, González-Maeso J.   +10 more
europepmc   +1 more source

Third-Generation Antipsychotics as Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Narrative Review of Efficacy and Tolerability. [PDF]

Biomedicines
Rosso G, Peracchia S, Rizzo Pesci N, Di Salvo G, Maina G.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

“Selective” serotonin 5-HT2A receptor antagonists

Biochemical Pharmacology, 2022
Blockade of the serotonin 5-HT2A G protein-coupled receptor (5-HT2AR) is a fundamental pharmacological characteristic of numerous antipsychotic medications, which are FDA-approved to treat schizophrenia, bipolar disorder, and as adjunctive therapies in major depressive disorder.
Austen B, Casey, Meng, Cui, Raymond G, Booth, Clinton E, Canal   +3 more
openaire   +2 more sources